Five online modules with 1-2 hours of content focused on Cannabis for therapeutic use may be completed a la carte by qualified medical professionals, or interested individuals 18 years of age or older.  Medical professionals can earn Continuing Medical Education (CME) units for each module successfully completed. During registration you will be asked to indicate whether you are taking the module(s) for CMEs or not.

Overview

Cannabis Logo Start Date: Modules available on demand
Learning Format: Online
Estimated Time Commitment: Approximately 1-2 hours per module – 5 modules available (Approximately 7.75 total hours)
Price: $100 per credit
Continuing Medical Education (CME): The University of Vermont College of Medicine is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing medical education for the healthcare team.

The University of Vermont designates this enduring material activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is made up of 5 individual modules that can be completed independently. This program has been reviewed and is approved for pharmacists for a maximum 7.75 hours/0.775 CEU ACPE  0621-0000-16-001-H01-P. To obtain a CE certificate for a CME module qualified pharmacists must complete the CME module in its entirety and an evaluation, and score 80% or higher on the post-assessment test for the module.

Audience: Designed for Clinicians, Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists.
Frequency: Available on-demand throughout the year by UVM’s Department of Pharmacology

Online Modules:

  1. MEDICO-LEGAL (1.25 hours) – Register for this Module
    • Cannabis History, Policy and Law
    • Public Health – Risks and Potential Benefits

 

  1. BIOLOGY AND BASIC SCIENCE (1.75 hours) – Register for this Module
    • The Endocannabinoid System
    • The Phytocannabinoids and Terpenes

 

  1. CLINICAL PRACTICE 1 – PHYSIOLOGY AND PHARMACOLOGY (2 hours) – Register for this Module
    • Physiological and Adverse Effects
    • Preparations and Dosage

 

  1. CLINICAL PRACTICE 2 –PAIN SYNDROMES (1.5 hours) –  Register for this Module
    • Clinical Practice – Chronic pain
    • Clinical Practice – Cancer and Palliative care

 

  1. CLINICAL PRACTICE 3 – MOTOR DISORDERS (1.25 hours) – Register for this Module
    • Clinical Practice – MS and Parkinson’s disease
    • Clinical Practice – Seizures

 

 

Learning Objectives

1. MEDICO-LEGAL

  • Cannabis History, Policy, and Law
    • Identify the key historical events associated with the medicinal use of Cannabis
    • Understand the process involved with medical Cannabis research
    • Contrast the rules, the regulations, and the federal issues of medicinal Cannabis in medical-legal states
    • Describe the roles of Medical Providers in different medical-legal states
  • Public Health – Risks and Potential Benefits
    • Identify the potential benefits – and risks – of cannabis-based medicine in adult and pediatric patients.
    • Describe four elements of patient and family education regarding cannabis.
    • Describe barriers for elderly patients to access cannabis-based medicine
    • Describe the role of caregivers for pediatric, disabled, and elderly patients receiving cannabis-based medicine

 

2. BIOLOGY AND BASIC SCIENCE

  • The Endocannabinoid System
    • Describe at least 3 unique characteristics of the endocannabinoid system
    • Explain implications of the endocannabinoid system on the use of cannabis as medication
    • Discuss the concept of endocannabinoid deficiency syndrome
  • The Phytocannabinoids and Terpenes
    • Identify phytocannabinoids, and contrast Marinol with cannabis occurring in nature
    • Understand the differences between phytocannabinoids
    • Describe terpenes and the entourage effect

 

3. CLINICAL PRACTICE 1 – PHYSIOLOGY AND PHARMACOLOGY

  • Physiological and Adverse Effects
    • Describe the pharmacology and toxicology of Cannabis and Cannabis-based products
    • Identify side effects associated with the acute and chronic use of medicinal cannabis
    • Describe cannabis’ effects on brain function in adolescents
    • Outline risk factors associated with the initiation or maintenance of cannabinoid therapies for pain, and strategies for referral when substance abuse is present
    • Explain risks to patients
  • Preparations and Dosage
    • Identify the cannabis-based pharmaceuticals currently available in the US market and abroad
    • Discuss four common routes of administration of cannabis
    • Discuss dosing and pharmacokinetics of medical marijuana
    • Explain to patients the pharmacology of cannabinoids and terpenes and the best indications for clinical use

 

4. CLINICAL PRACTICE 2 –PAIN SYNDROMES

  • Clinical Practice – Chronic Pain
    • Critically review and assess the current evidence for safety and efficacy of Cannabis and Cannabis-based products for chronic pain
    • Discuss decision-making strategies including non-cannabinoid and non-pharmacologic strategies for the management of pain
    • Determine which patients may benefit from using medicinal cannabis for chronic pain
    • Describe how to titrate medicinal cannabis to best manage chronic pain and ween patients from opioids
  • Clinical Practice – Cancer and Palliative Care
    • Critically review and assess the current evidence for safety and efficacy of cannabis products for cancer and palliative care
    • Assess when cannabis may be an appropriate treatment option for oncology patients, including specialties such as pediatric oncology
    • Identify the risks associated with the use of smoked cannabis in immunocompromised patients
    • Employ strategies that integrate care across disciplines
    • Create individualized care for special populations including patients requiring palliative care

 

5. CLINICAL PRACTICE 3 – MOTOR DISORDERS

  • Clinical Practice – MS and Parkinson’s Disease
    • Critically review and assess the current evidence for safety and efficacy of cannabis for MS and Parkinson’s disease
    • Explain the recent neuropharmacology of THC and the other cannabinoids
    • Apply evidence-based strategies for managing the patient with motor disorders, including formulation of the treatment plan when cannabinoids are used
    • Employ strategies that integrate care across disciplines
  • Clinical Practice – Seizures
    • Critically review and assess the current evidence for safety and efficacy of cannabis for seizures
    • Explain the recent research supporting the efficacy CBD for pediatric seizure conditions
    • Apply evidence-based strategies for managing the seizure patient, including formulation of the treatment plan when cannabinoids are used
    • Employ strategies that integrate care across disciplines

CME INFORMATION

The University of Vermont College of Medicine is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing medical education for the healthcare team.

The University of Vermont designates this enduring material activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is made up of 5 individual modules that can be completed independently. This program has been reviewed and is approved for pharmacists for a maximum 7.75 hours/0.775 CEU ACPE  0621-0000-16-001-H01-P. To obtain a CE certificate for a CME module qualified pharmacists must complete the CME module in its entirety and an evaluation, and score 80% or higher on the post-assessment test for the module.


 

Faculty

Kalev Freeman, MD, PhD

KalevFreemanKalev Freeman, MD, PhD is a physician-scientist with a background in molecular biology and specific research interest in inflammation and injury. He is Co-Founder of the Phytoscience Institute and the Medical Director of Vermont Patients Alliance Inc., a non-profit plant-based pharmaceutical research center that serves over 600 patients with debilitating medical conditions.  He directs several ongoing research studies, and has been invited to speak at medical conferences and public events throughout the United States.  Dr. Freeman completed his BA at the University of Michigan, and both his MD and PhD at the University of Colorado, where he specialized in molecular biology.

 

Monique McHenry, PhD

moniquemchenryMonique McHenry, PhD is a botanist with a background in plant diversity and evolution. She is Co-Founder of the Phytoscience Institute and the Executive Director of Vermont Patients Alliance Inc., a non-profit plant-based pharmaceutical research center, and active in legislation and lobbying. She is also the co-director of a Cannabis pharmacology course at the University of Vermont Medical School.  Dr. McHenry completed her BA and MSc at the University of Colorado, and her PhD at the University of Vermont, where she specialized in the diversity and evolution of plants.

 

Karen Lounsbury, PhD

Karen Lounsbury, PhD is a professor of pharmacology at the University of Vermont College of Medicine. Research in Dr. Lounsbury’s laboratory is focused on understanding mechanisms whereby signals generated at the plasma membrane are communicated to the nucleus of vascular cells to mediate vascular remodeling and angiogenesis. Signaling pathways of current interest include protein kinase cascades, hypoxia signaling and mechanisms of calcium-regulated gene transcription in arterial smooth muscle cells and ovarian tumor cells.

 

Wolfgang Dostmann, PhD

Wolfgang Dostmann, PhD is a professor of pharmacology at the University of Vermont College of Medicine, and teaches a course on cannabis pharmacology.  His research interests focus on the topic of second messenger signaling, and he and his team specialize in research on the contraction function of muscle cells in blood vessels. Dr. Dostmann’s research is stimulated by and integrated through the use of a large variety of methods and techniques ranging from organic chemistry, biochemistry, molecular biology, cell biology, biophysics, physiology and pharmacology.

 

Frances Carr, PhD

University of Vermont
Professor, Department of Pharmacology

 

John MacKay, PhD

Waters Technologies
Senior Director, Strategic Technologies

 

John McPartland, DO, MS
University of Vermont College of Medicine, Family Medicine Department

 

Tuition

Program Pricing:  $100 per credit

Module Cost per Module
MEDICO-LEGAL $125
BIOLOGY AND BASIC SCIENCE $175
CLINICAL PRACTICE 1 – PHYSIOLOGY AND PHARMACOLOGY $200
CLINICAL PRACTICE 2 –PAIN SYNDROMES $150
CLINICAL PRACTICE 3 – MOTOR DISORDERS $125

 

UVM Affiliates: 20% discount. UVM affiliates defined as UVM students, UVM alumni, UVM current and retired faculty and staff and their spouses and dependents, and UVM Medical Center employees, their spouses and dependents.

 

Registration

There is one combined application and registration process for this program. As part of that process applicants must verify that they are 18 years of age or older.

Qualified medical professionals may earn Continuing Medical Education units for each module successfully completed.  As part of the application/registration process you will be asked if you are seeking CME credit for your participation.

Online Modules:

  1. MEDICO-LEGAL (1.25 hours) – Register for this Module
  1. BIOLOGY AND BASIC SCIENCE (1.75 hours) – Register for this Module
  1. CLINICAL PRACTICE 1 – PHYSIOLOGY AND PHARMACOLOGY (2 hours) – Register for this Module
  1. CLINICAL PRACTICE 2 –PAIN SYNDROMES (1.5 hours) –  Register for this Module
  1. CLINICAL PRACTICE 3 – MOTOR DISORDERS (1.25 hours) – Register for this Module

CME INFORMATION

The University of Vermont College of Medicine is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing medical education for the healthcare team.

The University of Vermont designates this enduring material activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is made up of 5 individual modules that can be completed independently. This program has been reviewed and is approved for pharmacists for a maximum 7.75 hours/0.775 CEU ACPE  0621-0000-16-001-H01-P. To obtain a CE certificate for a CME module qualified pharmacists must complete the CME module in its entirety and an evaluation, and score 80% or higher on the post-assessment test for the module.